Associated Papers
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.
Stein CM et al.
Leukemia, 2026
Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.
Varty K et al.
Genes, Chromosomes & Cancer, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
Six-Color Multiplex Digital PCR Assays for Comprehensive Screening and Identification of Multiple Driver Mutations Associated with Pancreatic Carcinogenesis.
Maeda C et al.
Clinical Chemistry, 2026
RAS-variant allele frequency as a potential prognostic marker of overall survival in patients with metastatic colorectal cancer.
Nindra U et al.
Cancer Treatment and Research Communications, 2026
Mutational landscape of lung adenocarcinoma in Czechia.
Ambrozkiewicz F et al.
Cancer Treatment and Research Communications, 2026
Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.
Oh CR et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Hernandez S et al.
Lung Cancer (amsterdam, Netherlands), 2026
Prevalence of Genomic Alterations in EGFR, KRAS, NRAS, and BRAF Among Early-Stage Nonsquamous Non-Small Cell Lung Cancer in Brazil.
Marques FK et al.
Jco Global Oncology, 2026
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.
Ogura N et al.
Jco Precision Oncology, 2026
Prognostic Significance of SOX9 and Its Combination With RAS and TP53 Mutations Following Colorectal Cancer Liver Metastasectomy.
Duan JL et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077).
Song KW et al.
Molecular Cancer Therapeutics, 2025
Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.
Liu L et al.
Medcomm, 2025
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.
Navarro-Jiménez M et al.
Npj Precision Oncology, 2025
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer.
Haraguchi E et al.
International Journal of Cancer, 2025
IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation.
Wang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.
Hamza A et al.
British Journal of Cancer, 2025
Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort.
Tawel HM et al.
Cureus, 2025
Genetic Alteration Profiling in North Macedonian Lung Cancer Patients.
Eftimov A et al.
Genes, 2025
Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction.
Burge RA et al.
Cancer Research Communications, 2025
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.
Kavgaci G et al.
Molecular Oncology, 2025
The Impact of RAS/BRAF Mutation on Pathological Complete Response After Total Neoadjuvant Therapy in Rectal Cancer.
Aboelmaaty S et al.
Annals of Surgical Oncology, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea.
Shim YS et al.
Gynecologic Oncology Reports, 2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Yan S et al.
Translational Lung Cancer Research, 2025
Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.
Hartner S et al.
Nature Communications, 2025
Colorectal cancer tumor phenotypes associated with KRAS, NRAS, and BRAF hot-spot mutations.
Abdelgadir O et al.
World Journal of Gastrointestinal Pathophysiology, 2025
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.
Walter DM et al.
Biorxiv : the Preprint Server for Biology, 2025
Structural basis for LZTR1 recognition of RAS GTPases for degradation.
Dharmaiah S et al.
Science (new York, N.y.), 2025
Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.
Soloveva M et al.
International Journal of Molecular Sciences, 2025
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.
Gibbs P et al.
Clinical Colorectal Cancer, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation.
Shi Q et al.
Nature Genetics, 2025